The FDA as approved Crysvita® (burosumab-twza; Ultragenyx) for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback